Cargando…

The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line

The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carcinoma; however, many patients with advanced disease undergo relapse due to chemoresistance. Drug repurposing coupled with a combination of two or more compounds with independent mechanisms of action ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunes, Mariana, Duarte, Diana, Vale, Nuno, Ricardo, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820586/ https://www.ncbi.nlm.nih.gov/pubmed/36613537 http://dx.doi.org/10.3390/ijms24010097

Ejemplares similares

Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma
por: Nunes, Mariana, et al.
Publicado: (2022)

Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action
por: Duarte, Diana, et al.
Publicado: (2022)

Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines
por: Duarte, Diana, et al.
Publicado: (2021)

New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells
por: Duarte, Diana, et al.
Publicado: (2020)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021)

Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs
por: Duarte, Diana, et al.
Publicado: (2021)

Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches
por: Vale, Nuno, et al.
Publicado: (2022)

Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein
por: Nunes, Mariana, et al.
Publicado: (2021)

Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein
por: Nunes, Mariana, et al.
Publicado: (2022)

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017)

Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
por: Matthews, Bayley G., et al.
Publicado: (2021)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

Pleiotropic effects of pitavastatin
por: Davignon, Jean
Publicado: (2012)

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
por: Wong-Brown, Michelle W., et al.
Publicado: (2022)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

The potential of metformin as an antineoplastic in brain tumors: A systematic review
por: Takhwifa, Famila, et al.
Publicado: (2021)

Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses
por: Wu, Yong, et al.
Publicado: (2020)

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2021)

Interaction of the pitavastatin with model membranes
por: Shurshalova, Guzel S., et al.
Publicado: (2021)

Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
por: Alfaro, Yunuen, et al.
Publicado: (2013)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
por: Ghaffari, Abdi, et al.
Publicado: (2018)

Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
por: Tsujita, Kenichi, et al.
Publicado: (2023)

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010)

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers
por: Gull, Nicole, et al.
Publicado: (2022)

Pitavastatin in cardiometabolic disease: therapeutic profile
por: Masana, Luis
Publicado: (2013)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Pitavastatin: evidence for its place in treatment of hypercholesterolemia
por: Alagona, Peter
Publicado: (2010)

Effect of Pitavastatin on Vascular Reactivity in Hypercholesterolemic Rabbits
por: de Almeida, Eros Antonio, et al.
Publicado: (2014)

Chloride intracellular channel 1 regulates the antineoplastic effects of metformin in gallbladder cancer cells
por: Liu, Yongchen, et al.
Publicado: (2017)

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
por: Wang, Yan, et al.
Publicado: (2023)

Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism
por: Liu, Yong, et al.
Publicado: (2017)

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
por: Zhang, Jing, et al.
Publicado: (2021)

Antineoplastic activity of rinvanil and phenylacetylrinvanil in leukaemia cell lines
por: LUVIANO, AXEL, et al.
Publicado: (2014)

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis
por: Zanotti, Laura, et al.
Publicado: (2017)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jk9qeev3a1t4flq1ueoh6rscbh